NASDAQ · ONCO

Onconetix, Inc.

Healthcare · Biotechnology

$0.64▼ 3.69% ($0.02)at close

After hours$0.66▲ 2.80%7:55 PM ET

52-week

$0.59$209.50

Market cap

No multiple

Valuation

Recommended · Earnings yield

Price used

$0.64

Earnings yield

Unavailable

Reported earnings

10-year Treasury benchmark: 5%

USD · Financial statements through 2026-06-30 · EPS source period not supplied

A positive earnings figure and a usable price are needed to calculate earnings yield.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: Financial statements through 2026-06-30 · EPS source period not supplied
Data refreshed: Sep 20, 2026, 10:16 AM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 4 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -99.57%Revenue (TTM): -51.33%FCF (TTM): -88.09%

What changed

The stock fell 99.57% over the last year. Revenue declined 51.33% over the trailing twelve months. Operating margin moved from -2,621.48% to -1,265.55%. Free cash flow declined 88.09% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Operating margin stands at -1,265.55%. Revenue declined 51.33% — this read reverses if that trend stabilizes. Free cash flow fell 88.09% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide.

CEODavid Allan White

SectorHealthcare

IndustryBiotechnology

Employees2

IPO dateFeb 18, 2022

https://www.onconetix.com

Market multiples

Forward P/E—

EV/EBITDA-18.91

Enterprise value$250.82M

Stock splits

May 21, 2026↓ Reverse

Every 10 shares became 1

-90%

Mar 25, 2026↓ Reverse

Every 5 shares became 1

-80%

Jun 13, 2025↓ Reverse

Every 85 shares became 1

-99%

Sep 24, 2024↓ Reverse

Every 40 shares became 1

-97%

Profitability & growth

Revenue growth-83.92%

Gross margin (FY2025)77.62%▲35.8ppvs FY2024

Operating margin (FY2025)-778.16%▲1459.8ppvs FY2024

ROE-105.23%▲5.4ppvs FY2025

Analyst consensus

RatingBuy

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 12, 2026

Q4 FY26 · EPS est -$45,050.00 · Revenue est $17.46K

View